<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523339</url>
  </required_header>
  <id_info>
    <org_study_id>UI-CRVO-2015</org_study_id>
    <nct_id>NCT02523339</nct_id>
  </id_info>
  <brief_title>Study of Retinal Oxygenation in Central Retinal Vein Occlusion</brief_title>
  <official_title>Multicenter Study of Retinal Oxygenation in Central Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iceland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center Memorial A. de Rothschild</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Palacky University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toyama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iceland</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to test if oxygen saturation in retinal vessels is correlated&#xD;
      with clinical parameters, such as visual acuity, central retinal thickness and presence of&#xD;
      neovascularization. Retinal oximetry is performed with fundus camera based oximeters. The&#xD;
      study will not entail change in treatment of the disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">November 3, 2020</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal vessel oxygen saturation</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence or absence of ocular neovascularisation</measure>
    <time_frame>12 months</time_frame>
    <description>As determined by gonioscopic examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal vessel oxygen saturation</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of ocular neovascularisation</measure>
    <time_frame>Baseline</time_frame>
    <description>As determined by gonioscopic examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal vessel oxygen saturation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of ocular neovascularisation</measure>
    <time_frame>3 months</time_frame>
    <description>As determined by gonioscopic examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal vessel oxygen saturation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of ocular neovascularisation</measure>
    <time_frame>6 months</time_frame>
    <description>As determined by gonioscopic examination</description>
  </secondary_outcome>
  <enrollment type="Actual">117</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspected central retinal vein occlusion (CRVO) will be invited to&#xD;
        participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspected central retinal vein occlusion.&#xD;
&#xD;
          -  Informed consent for participation.&#xD;
&#xD;
          -  No treatment before the first oximetry measurement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other retinal disease. Glaucoma and diabetes without retinopathy are not&#xD;
             exclusion criteria but should be registered.&#xD;
&#xD;
          -  History of cardiovascular or respiratory diseases that can be expected to influence&#xD;
             systemic or retinal oxygen saturation. Examples: Known COPD or carotid stenosis.&#xD;
             Subjects with high blood pressure will not be excluded but blood pressure should be&#xD;
             registered.&#xD;
&#xD;
          -  Poor quality images will be excluded based on the images themselves. Therefore,&#xD;
             grading of cataract or other media opacities is not strictly necessary for the purpose&#xD;
             of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sveinn H. Hardarson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iceland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, University Hospital and Faculty of Medicine and Dentistry, Palacky University Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University. Department of Clinical Medicine - The Department of Ophthalmology</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iceland / Landspitali, Dept. of Ophthalmology</name>
      <address>
        <city>Reykjavik</city>
        <zip>101</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Clinic of the University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4055</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center Memorial A. de Rothschild</name>
      <address>
        <city>Geneva</city>
        <zip>1208</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aston University School of Life and Health Sciences</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Iceland</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 7, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iceland</investigator_affiliation>
    <investigator_full_name>Sveinn Hakon Hardarson</investigator_full_name>
    <investigator_title>Post-doctoral researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

